ATE250938T1 - Verfahren zur verbesserung der absorption und des transport von lipidlöslichen verbindungen mittels strukturierter glyceriden - Google Patents

Verfahren zur verbesserung der absorption und des transport von lipidlöslichen verbindungen mittels strukturierter glyceriden

Info

Publication number
ATE250938T1
ATE250938T1 AT98960729T AT98960729T ATE250938T1 AT E250938 T1 ATE250938 T1 AT E250938T1 AT 98960729 T AT98960729 T AT 98960729T AT 98960729 T AT98960729 T AT 98960729T AT E250938 T1 ATE250938 T1 AT E250938T1
Authority
AT
Austria
Prior art keywords
carbon atoms
acyl moieties
absorption
structured
transport
Prior art date
Application number
AT98960729T
Other languages
English (en)
Inventor
Stephen J Demichele
Theresa W Lee
Patrick Tso
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE250938T1 publication Critical patent/ATE250938T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/10—Ester interchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT98960729T 1997-12-16 1998-12-04 Verfahren zur verbesserung der absorption und des transport von lipidlöslichen verbindungen mittels strukturierter glyceriden ATE250938T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/991,503 US6013665A (en) 1997-12-16 1997-12-16 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
PCT/US1998/025741 WO1999030740A1 (en) 1997-12-16 1998-12-04 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides

Publications (1)

Publication Number Publication Date
ATE250938T1 true ATE250938T1 (de) 2003-10-15

Family

ID=25537282

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960729T ATE250938T1 (de) 1997-12-16 1998-12-04 Verfahren zur verbesserung der absorption und des transport von lipidlöslichen verbindungen mittels strukturierter glyceriden

Country Status (18)

Country Link
US (2) US6013665A (de)
EP (1) EP1037666B1 (de)
JP (1) JP2002508336A (de)
AT (1) ATE250938T1 (de)
AU (1) AU739233B2 (de)
BR (1) BR9813474A (de)
CA (1) CA2315224A1 (de)
DE (1) DE69818704T2 (de)
DK (1) DK1037666T3 (de)
ES (1) ES2209228T3 (de)
HU (1) HUP0100430A2 (de)
IL (1) IL135271A0 (de)
NO (1) NO20002306L (de)
NZ (1) NZ503666A (de)
PL (1) PL341208A1 (de)
PT (1) PT1037666E (de)
TR (1) TR200001563T2 (de)
WO (1) WO1999030740A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US7097849B2 (en) * 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
US6835408B2 (en) 1998-11-13 2004-12-28 The Nisshin Oillio Group, Ltd. Oil or fat composition
US20070244192A1 (en) * 1999-01-14 2007-10-18 Martek Biosciences Corporation Plant seed oils containing polyunsaturated fatty acids
US7247461B2 (en) * 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
US7211418B2 (en) * 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR024570A1 (es) * 1999-06-18 2002-10-16 Merck Patent Gmbh Una composicion farmaceutica para uso oral, un metodo para su manufacturacion y un metodo para su estabilizacion.
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
IL135335A (en) * 2000-03-29 2013-12-31 Lycored Natural Prod Ind Ltd Use of Carotenoids in Preparing Pharmaceuticals to Prevent Adverse Effects from Hormones and Pharmaceuticals Containing Carotenoids
JP2004527501A (ja) * 2001-03-05 2004-09-09 ピー． アーネスト，スティーヴン 経腸処方
KR20020081632A (ko) * 2001-04-19 2002-10-30 (주)라이브맥스 Ｃｌａ가 함유된 재구성 지질의 제조방법 및 이용방법
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
JP3980851B2 (ja) * 2001-08-30 2007-09-26 有限会社ゴトーコーポレーション 固型製剤、その製造方法、及び食品
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
US6793959B2 (en) * 2002-03-18 2004-09-21 Bunge Foods Corporation Low viscosity structured lipid pan release compositions and methods
US7247334B2 (en) * 2002-03-18 2007-07-24 Bunge Oils, Inc. Low-residue, easy-cleaning and low-viscosity structured lipid pan release compositions and methods
ATE492166T1 (de) * 2002-04-05 2011-01-15 Nestle Sa Zusammensetzungen und verfahren zur verbesserung von lipidassimilation in haustieren
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US7041840B2 (en) * 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050196434A1 (en) * 2004-03-04 2005-09-08 Brierre Barbara T. Pharmaceutical composition and method for the transdermal delivery of magnesium
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
DK1802312T3 (en) * 2004-10-20 2015-12-14 Endorech Inc Kønssteroidudgangsstof in combination with a selective estrogen receptor modulator for the prevention and treatment of vaginal atrophy in post-menopausal women
KR101332869B1 (ko) * 2005-04-15 2013-11-25 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 항-ｅｇｆｒ 치료법에 속발된 피부 발진의 예방 및 치료를위한 비타민 ｋ
EP2979699A1 (de) 2005-04-15 2016-02-03 Clarus Therapeutics, Inc. Systeme zur pharmazeutischen verabreichung hydrophober wirkstoffe und zusammensetzungen damit
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US20070218183A1 (en) * 2006-03-14 2007-09-20 Bunge Oils, Inc. Oil composition of conjugated linoleic acid
WO2007106903A2 (en) 2006-03-15 2007-09-20 Martek Biosciences Corporation Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
EP2031974A1 (de) * 2006-05-17 2009-03-11 Ziscoat N.V. Fettsäuretriglyceride zur herstellung von biologisch kompatiblen beschichtungen
US9428582B2 (en) * 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
CA2558202A1 (en) * 2006-09-14 2006-11-23 Reinhold W. Vieth Vitamin d compositions and method of administration to infants
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US8206772B2 (en) * 2007-11-08 2012-06-26 Kraft Foods Global Brands Llc Structured lipid compositions and methods of formulation thereof
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100196577A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals comprising citrus limonoids and application to sports drinks
US9545117B2 (en) * 2009-02-03 2017-01-17 Tropicana Products, Inc. Microencapsulated citrus phytochemicals and application to beverages
US20100196549A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals and application to sports drinks
US20100196554A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals comprising citrus limonoids and application to beverages
EP2408797B1 (de) 2009-03-19 2017-03-15 DSM IP Assets B.V. Nukleinsäuremoleküle und polypeptide aus pufa-synthasen, zusammensetzungen und verfahren zu ihrer herstellung und verwendung
TW201112967A (en) 2009-09-16 2011-04-16 Abbott Lab Dryblended nutritional powders
TW201121431A (en) 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
TWI492744B (zh) * 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
CA2786710C (en) 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
WO2011126891A2 (en) * 2010-03-30 2011-10-13 Kraft Foods Global Brands Llc Lipid compositions for increased fatty and creamy mouthfeel and uses thereof
EP2397038A1 (de) 2010-06-21 2011-12-21 Abbott Laboratories Frühe Programmierung der Hirnfunktion durch Sojaproteinzufuhr
EP2422629A1 (de) 2010-08-23 2012-02-29 Abbott Laboratories Verfahren zur Verbesserung der Kognition/von Gedächtnis mit Hilfe von Maltodextrin
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012092088A1 (en) 2010-12-29 2012-07-05 Abbott Laboratories Nutritional products including a novel fat system including monoglycerides
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
NL2007268C2 (en) 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
EP2934190B1 (de) 2012-12-20 2018-12-12 Abbott Laboratories Nährstoffformulierungen mit muttermilcholigosacchariden zur modulierung von entzündungen
AU2015303835B2 (en) 2014-08-12 2020-04-09 Monash University Lymph directing prodrugs
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
DK3355701T3 (da) 2015-10-01 2021-01-25 Frieslandcampina Nederland Bv Væskeformig ernæringssammensætning, der omfatter micellært kasein og hydrolyseret valleprotein
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A3 (de) 2017-08-29 2024-09-11 PureTech LYT, Inc. An das lymphatische system gerichtete lipidprodrugs
CN111246872A (zh) 2017-10-30 2020-06-05 菲仕兰坎皮纳荷兰公司 治疗和/或预防肌肉质量和/或力量损失相关病症的蛋白质稠密的营养组合物
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
EP3727362A4 (de) 2017-12-19 2021-10-06 PureTech LYT, Inc. Lipidprodrugs von mycophenolsäure und ihre verwendungen
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン，インク． 肝臓病
US20220047611A1 (en) * 2018-09-11 2022-02-17 Parapharm Development Limited Capsule, Tablet or Pill
MX2021002916A (es) 2018-09-14 2021-08-24 Puretech Lyt 100 Inc Pirfenidona enriquecida con deuterio y métodos para su uso.
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids
CN115397457A (zh) 2020-04-06 2022-11-25 雅培制药有限公司 用于调节呼吸诱导的细胞因子的营养制剂
WO2022177965A1 (en) 2021-02-16 2022-08-25 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en) 2021-04-23 2022-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods and compositions for treating gas
WO2023159093A1 (en) 2022-02-16 2023-08-24 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
WO1986001715A1 (en) * 1984-09-13 1986-03-27 Center For Nutritional Research Charitable Trust Triglyceride preparations for the prevention of catabolism
US4753963A (en) * 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
US5081105A (en) * 1988-01-15 1992-01-14 New England Deaconess Hospital Corporation Method of treating cancer using structured lipids
JP2677613B2 (ja) * 1988-06-24 1997-11-17 エーザイ株式会社 ビタミンｅ又はその誘導体の吸収促進組成物
US5601860A (en) * 1990-11-30 1997-02-11 American Home Products Corporation Corandomized fat compositions for infant formulas
EP0583337A1 (de) * 1991-05-08 1994-02-23 Novo Nordisk A/S Verwendung eines lipids zur herstellung eines enteralen pharmazeutischen präparates zur behandlung von lipid-malabsorption
CA2151820C (en) * 1993-01-15 2000-11-28 Stephen Joseph Demichele Structured lipids
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
DE4417851C1 (de) * 1994-05-20 1995-10-05 Horst Heirler Diätetisches Lebensmittel mit mittelkettigen Fettsäuren und dessen Verwendung
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia

Also Published As

Publication number Publication date
EP1037666B1 (de) 2003-10-01
ES2209228T3 (es) 2004-06-16
IL135271A0 (en) 2001-05-20
WO1999030740A1 (en) 1999-06-24
PT1037666E (pt) 2004-02-27
CA2315224A1 (en) 1999-06-24
NO20002306L (no) 2000-06-16
NO20002306D0 (no) 2000-04-28
DK1037666T3 (da) 2004-02-09
DE69818704D1 (de) 2003-11-06
JP2002508336A (ja) 2002-03-19
DE69818704T2 (de) 2004-07-29
EP1037666A1 (de) 2000-09-27
PL341208A1 (en) 2001-03-26
BR9813474A (pt) 2000-10-10
US6013665A (en) 2000-01-11
HK1032744A1 (en) 2001-08-03
HUP0100430A2 (hu) 2001-08-28
US6160007A (en) 2000-12-12
NZ503666A (en) 2002-03-01
TR200001563T2 (tr) 2000-10-23
AU1625699A (en) 1999-07-05
AU739233B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ATE250938T1 (de) Verfahren zur verbesserung der absorption und des transport von lipidlöslichen verbindungen mittels strukturierter glyceriden
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
RU93058379A (ru) Фармацевтическая композиция, содержащая определенную липидную систему, способ получения композиции и ее применение
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
FI972431A7 (fi) Sytotoksisten T-lymfosyyttivasteiden induktio
ATE113604T1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DE59510233D1 (de) Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
RU2002123877A (ru) Кахалалидные соединения
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
RU93053905A (ru) Оксипуриновые нуклеозиды и родственные им соединения, а также их ацильные производные для улучшения гемопоэза, фармацевтическая композиция и способ лечения и/или профилактики
ATE110268T1 (de) Verfahren und mittel zur behandlung der alzheimer-krankheit, verwandter demenzen und epilepsie.
PT1057826E (pt) Derivados carboxamidicos dimericos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
FI914410A0 (fi) Kalciumupptagande inhibitorer.
MX169075B (es) Composicion cosmetica para el cabello
KR890701118A (ko) 혈소판 감소증 예방 및 치료제
DK0817643T3 (da) Forbindelser og præparater til administration af aktive midler
RU95106650A (ru) Фармацевтические композиции для предотвращения образования метастазов рака в печени и фармацевтическая композиция для лечения рака печени, способ лечения, способ получения композиции, применение цитарабин окфосфата для получения фармацевтической композиции
MX9604984A (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.
ITRM910038A1 (it) Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.
TNSN91040A1 (fr) Derives de benzofuranne

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1037666

Country of ref document: EP

REN Ceased due to non-payment of the annual fee